The story appears on

Page A10

September 13, 2016

GET this page in PDF

Free for subscribers

View shopping cart

Related News

Home » Business » Consumer

Horizon to buy Raptor

HORIZON Pharma will spend about US$800 million to buy Raptor Pharmaceutical and expand its portfolio of rare disease treatments, a growing area of focus for drugmakers.

The Ireland-based drug developer said yesterday that the deal will strengthen its business in the United States and provide a platform to expand in Europe and other international markets.

Raptor’s portfolio includes Procysbi, which treats a rare metabolic disorder, and Quinsair, approved for managing a chronic pulmonary infection in adult patients with cystic fibrosis.

Horizon Pharma will pay US$9 in cash for each share of Raptor Pharmaceutical Corp and expects to finalize the purchase in the fourth quarter.




 

Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.

沪公网安备 31010602000204号

Email this to your friend